(Q33469688)

27 July 2017

title

Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology (English)

1 reference

27 July 2017

Lars Neumann

1

1 reference

27 July 2017

Allegra Ritscher

series ordinal

2

1 reference

27 July 2017

Gerhard Müller

series ordinal

3

1 reference

27 July 2017

Doris Hafenbradl

series ordinal

4

1 reference

27 July 2017

publication date

17 June 2009

1 reference

Journal of Computer - Aided Molecular Design

27 July 2017

published in

1 reference

27 July 2017

volume

23

1 reference

27 July 2017

issue

8

1 reference

27 July 2017

page(s)

501-511

1 reference

Molecular complexity and its impact on the probability of finding leads for drug discovery

27 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10822-009-9288-X

Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition

21 January 2018

1 reference

12 December 2020

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

1 reference

12 December 2020

Chemical fragments as foundations for understanding target space and activity prediction.

1 reference

12 December 2020

Biochemical mechanisms of drug action: what does it take for success?

1 reference

12 December 2020

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

12 December 2020

Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors

1 reference

12 December 2020

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

12 December 2020

Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety

1 reference

12 December 2020

Drug-target residence time and its implications for lead optimization

1 reference

12 December 2020

Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system.

1 reference

12 December 2020

Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase

1 reference

12 December 2020

Pursuing the leadlikeness concept in pharmaceutical research.

1 reference

12 December 2020

Deconstructing fragment-based inhibitor discovery

1 reference

12 December 2020

Recent developments in fragment-based drug discovery

1 reference

12 December 2020

The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

1 reference

12 December 2020

Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

1 reference

12 December 2020

Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition

1 reference

12 December 2020

10.1007/S10822-009-9288-X

Identifiers

DOI

1 reference

journals/jcamd/NeumannRMH09

27 July 2017

DBLP publication ID

1 reference

DBLP Dataset 2021-01-02

28 January 2021

1 reference